Lin-Wen Wu
Overview
Explore the profile of Lin-Wen Wu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
159
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Wu L, Zhou D, Zhang Z, Zhang J, Zhu H, Lin N, et al.
Biochem Biophys Res Commun
. 2019 Apr;
512(4):852-858.
PMID: 30929918
Regorafenib has been approved to treat patients who have HCC progression after sorafenib failure, however, regorafenib also faces the risk of drug resistance and subsequent progression of HCC patients. As...
12.
Hu X, Wu L, Weng X, Lin N, Zhang C
Oncol Lett
. 2018 Jul;
16(2):2715-2724.
PMID: 30013667
High-dose erlotinib is effective for non-small cell lung cancer patients with brain metastases. The aim of the present study was to investigate whether aspirin could increase the anti-proliferative and anti-metastatic...
13.
Hu X, Wu L, Zhang Z, Chen M, Li Y, Zhang C
Biochem Biophys Res Commun
. 2018 Jun;
503(2):1123-1129.
PMID: 29944884
Lung squamous cell carcinoma (LSCC) is a common type of non-small-cell lung cancer (NSCLC) and lacks effective treatment. Regorafenib, an oral multikinase inhibitor, has demonstrated promising anti-tumor activity in various...
14.
Li Y, Zhang N, Hu X, Chen J, Rao M, Wu L, et al.
Biochem Biophys Res Commun
. 2018 Mar;
498(3):481-486.
PMID: 29505792
Hypoxia promotes HCC progression and therapy resistance, and there is no systemic treatment for HCC patients after sorafenib resistance. Thus, it is urgent to develop potential therapeutic regimens for HCC...